Craig-Hallum analyst Alexander Nowak maintained a Buy rating on Exact Sciences (EXAS – Research Report) today. The company’s shares closed last Friday at $60.97.
According to TipRanks, Nowak is a 2-star analyst with an average return of 0.2% and a 39.87% success rate. Nowak covers the Healthcare sector, focusing on stocks such as CVRx, QuidelOrtho, and CareDx.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Exact Sciences with a $89.67 average price target, a 47.07% upside from current levels. In a report released today, Benchmark Co. also reiterated a Buy rating on the stock with a $91.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
EXAS market cap is currently $11.03B and has a P/E ratio of -38.59.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exact Sciences (EXAS) Company Description:
Founded in 1995, Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer.
Read More on EXAS:
- LLY, CVS, EXAS: Which Strong-Buy-Rated Healthcare Stock Is the Better Buy?
- Is EXAS a Buy, Before Earnings?
- BIIB, ZTS, EXAS: Which “Strong Buy” Healthcare Stock is Best?
- Exact Sciences (NASDAQ:EXAS) Announces Strong Preliminary Q4 Results and CFO Transition
- Exact Sciences says Jeff Elliott stepping down as executive VP, CFO
